Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 74   

Articles published

APPY 0.220 -0.020 (-8.33%)
price chart
Venaxis Inc (APPY) Given New $0.50 Price Target at Canaccord Genuity
Venaxis Inc logo Venaxis Inc (NASDAQ:APPY) had its target price decreased by Canaccord Genuity from $1.00 to $0.50 in a research note published on Wednesday morning, Market Beat Ratings reports.
Analyst Coverage Updates - Venaxis, Inc. (APPY)
Recently stock market analysts have updated their consensus ratings on shares of Venaxis, Inc. (APPY). The latest broker reports which are currently outstanding on Thursday 11th of February state 0 analysts have a rating of “strong buy”, 0 analysts ...
Venaxis Inc (NASDAQ:APPY) Had Its Price Target Lowered by 50.00 % at Canaccord ...
In a research report revealed to investors and clients by Canaccord Genuity on Wednesday, 10 February, Venaxis Inc (NASDAQ:APPY) had its PT cut to $0.50.
Venaxis Inc (APPY) Price Target Cut to $0.50  Intercooler Financial
Venaxis Receives a Hold from Canaccord Genuity  Analyst Ratings
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Glancy ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of a class (the “Class”) comprising purchasers of the securities ...
Venaxis Inc (APNB) Q2 2015 Sentiment
Venaxis Inc (APNB) hedge funds sentiment decreased to 0.44 in Q2 2015. Its down -0.02, from 0.46 in 2015Q1. The sentiment has dropped, as 4 investment professionals increased and started new stock positions, while 9 trimmed and sold stock positions in ...
Venaxis Announces Transaction with Strand Life Sciences
CASTLE ROCK, Colo., Jan. 26, 2016 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders.
Venaxis to merge with Strand Life Sciences  Seeking Alpha
Venaxis Due Off Halt at 440 PM ET, to Combine With Strand Life Sciences ...  WallStreet.org
Venaxis Inc (APPY) Stock Crashes On FDA's “Not Substantially Equivalent” Response
Venaxis Inc (NASDAQ:APPY) has received "not substantially equivalent" remarks on its blood-based diagnostic test, APPY1, from the US Food and Drug Administration (FDA).
Venaxis' appendicitis test not found equivalent to standard care  Reuters
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  PR Newswire (press release)
Venaxis, Inc. (NASDAQ:APPY) Short Interest Update
Venaxis, Inc. (NASDAQ:APPY) has witnessed a rise of 3.7% or 21,143 shares in its short figure. The short interest augmentation took it from 578,803 on December 31,2015 to 599,946 on January 15,2016.
Venaxis announces transaction with Strand Life Sciences to merge as combined ...  pharmabiz.com
Price Target Update On Venaxis, Inc. (APPY)
01/29/2015 - Venaxis, Inc. was downgraded to “hold” by analysts at Craig-Hallum. The share price of Venaxis, Inc. (APPY) was up +2.00% during the last trading session, with a day high of 0.26. 159414 shares were traded on Venaxis, Inc.'s last session.
Why Numerous Upside Scenarios Make Venaxis A Biotech To Buy (APPY)
With news being very light on names that I cover over the past few weeks, I wanted to initiate a new name today: Venaxis (NASDAQ:APPY).